A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03690154 |
Recruitment Status :
Terminated
(Despite demonstrated safety and tolerability the trial was terminated early due to program re-prioritization in light of the competitive landscape.)
First Posted : October 1, 2018
Last Update Posted : July 13, 2022
|
Sponsor:
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Information provided by (Responsible Party):
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Terminated |
---|---|
Actual Primary Completion Date : | February 11, 2022 |
Actual Study Completion Date : | February 11, 2022 |